Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/31 cls

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Canaccord

Salveen Richter

Price target

Buy

21%

$72.83

JPMorgan

Cory Kasimov

Price target

Overweight

Richter raised her target to $90 from $54 based on a physician tracking survey assessing the launch of Juxtapid lomitapide for homozygous familial hypercholesterolemia (hoFH). Of 213 patients surveyed, 7 had Juxtapid scripts and 5 patients were on the drug, translating to about 7% of the about 3,000 U.S. hoFH patients. Based on the survey, Richter has increased confidence in her 2013 Juxtapid revenue expectation of $28.2M vs. consensus estimate of $28.9M and company guidance of $15M. She previously expected 2013 revenues of $25.5M and now expects peak worldwide revenue of about $895M in 2024.